Leerink Partners analyst Marc Goodman maintained a Buy rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target ...

Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.

Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

How is one of the world’s largest pharmaceutical companies promoting sustainability and regulatory compliance throughout its ...